Trial reportBiological psychiatry2011
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Trial report in Biological psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- The Association Between Chronic Tobacco Smoking and Brain Alterations in Schizophrenia: A Systematic Review of Magnetic Resonance Imaging Studies.Schizophrenia bulletin · 2025Pooled it
- Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.Journal of clinical psychopharmacology · 2018Trial
- Nicotinic modulation of salience network connectivity and centrality in schizophrenia.Journal of psychiatric research · 2017Trial
- Nicotine restores functional connectivity of the ventral attention network in schizophrenia.Neuropharmacology · 2016Trial
- Neuronal effects of nicotine during auditory selective attention in schizophrenia.Human brain mapping · 2016Trial
- A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the α7 nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats.Frontiers in neuroscience · 2023Article
- Nicotinic receptor modulation of the default mode network.Psychopharmacology · 2021Article
- The role of nicotinic cholinergic neurotransmission in delusional thinking.NPJ schizophrenia · 2020Review
- Sensitivity of Neuroimaging Indicators in Monitoring the Effects of Interferon Gamma Treatment in Friedreich's Ataxia.Frontiers in neuroscience · 2020Article
- Preservation Effect: Cigarette Smoking Acts on the Dynamic of Influences Among Unifying Neuropsychiatric Triple Networks in Schizophrenia.Schizophrenia bulletin · 2019Article
- Characteristic changes in the default mode network in hypertensive patients with cognitive impairment.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
- Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Review
- Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Article
- Cognitive Control, the Anterior Cingulate, and Nicotinic Receptors: A Case of Heterozygote Advantage.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Venom based neural modulators.Experimental and therapeutic medicine · 2018Article
- Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.Journal of psychopharmacology (Oxford, England) · 2017Review
- Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.Schizophrenia research. Cognition · 2016Article
- Perinatal Phosphatidylcholine Supplementation and Early Childhood Behavior Problems: Evidence for CHRNA7 Moderation.The American journal of psychiatry · 2016Article
- Top-Down Network Effective Connectivity in Abstinent Substance Dependent Individuals.PloS one · 2016Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
background3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of schizophrenia. This study examined the effects of DMXB-A on default network activity as a biomarker for drug effects on pathologic brain function associated with schizophrenia.
methodsPlacebo and two doses of DMXB-A were administered in a random, double-blind crossover design during a Phase 2 study of DMXB-A. Functional magnetic resonance imaging was performed on 16 nonsmoking patients with schizophrenia while they performed a simple eye movement task. Independent component analysis was used to identify the default network component. Default network changes were evaluated in the context of a polymorphism in CHRNA7, the α7-nicotinic acetylcholine receptor subunit gene, which was previously found to be associated with schizophrenia.
resultsCompared with placebo, both 150 and 75 mg twice daily DMXB-A altered default network activity, including a reduction in posterior cingulate, inferior parietal cortex, and medial frontal gyrus activity and an increase in precuneus activity. The most robust difference, posterior cingulate activity reduction, was affected by CHRNA7 genotype.
conclusionsThe observed DMXB-A-related changes are consistent with improved default network function in schizophrenia. Pharmacogenetic analysis indicates mediation of the effect through the α7-nicotinic receptor. These results further implicate nicotinic cholinergic dysfunction in the disease and suggest that default network activity may be a useful indicator of biological effects of novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.